XJPX4586
Market cap18mUSD
Dec 30, Last price
82.00JPY
1D
2.50%
1Q
-16.33%
Jan 2017
-82.81%
IPO
-97.44%
Name
Medrx Co Ltd
Chart & Performance
P/E
—
P/S
98.44
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
35.19%
Revenues
29m
-51.25%
Net income
-932m
L-16.12%
CFO
-913m
L-14.93%
Profile
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer's disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 29,000 -51.25% | 59,482 612.36% | |||
Cost of revenue | 961,000 | 1,157,619 | |||
Unusual Expense (Income) | |||||
NOPBT | (932,000) | (1,098,137) | |||
NOPBT Margin | |||||
Operating Taxes | 2,000 | 1,837 | |||
Tax Rate | |||||
NOPAT | (934,000) | (1,099,974) | |||
Net income | (932,000) -16.12% | (1,111,150) 4.84% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 1,637,745 | 352,132 | |||
BB yield | -31.19% | -14.61% | |||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | 30,000 | 22,358 | |||
Net debt | (1,805,000) | (1,078,025) | |||
| Cash flow | |||||
Cash from operating activities | (913,000) | (1,073,292) | |||
CAPEX | (759) | (1,958) | |||
Cash from investing activities | (1,958) | ||||
Cash from financing activities | 1,639,492 | 356,315 | |||
FCF | (888,670) | (1,055,880) | |||
| Balance | |||||
Cash | 1,720,000 | 994,025 | |||
Long term investments | 85,000 | 84,000 | |||
Excess cash | 1,803,550 | 1,075,051 | |||
Stockholders' equity | 7,000 | (1,852,204) | |||
Invested Capital | 1,946,000 | 3,068,553 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 34,778 | 25,363 | |||
Price | 151.00 58.95% | 95.00 -25.78% | |||
Market cap | 5,251,418 117.94% | 2,409,529 -11.86% | |||
EV | 3,446,418 | 1,331,504 | |||
EBITDA | (886,435) | (1,051,719) | |||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||